FDA approves first new molecular entity under national priority voucher program
1 aprile 2026
Leggi
The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis
Sillassen CDB, Faltermeier P, Bjerg JL, et al.
BMC Med. Pub. online 27 Mar 2026.
Leggi
Safety of semaglutide after dialysis initiation: an individual-level pooled analysis
Klein KR, Menacher A, Buse JB, et al.
Diabetes Care. Pub. online 26 Mar 2026.
Leggi
Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial
Marston NA, Bohula EA, Bhatia AK, et al.
JAMA. Pub. online 28 Mar 2026.
Leggi
Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial
Nissen SE, Wolski K, D’Alessio D, et al.
JAMA Cardiol. Pub. online 28 Mar 2026.
Leggi
Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: a comprehensive updated systematic review and meta-analysis
Mitchell S, Patwardhan K, Lucocq J, et al.
Diabet Med. Pub. online 28 Mar 2026.
Leggi
Lower risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease who initiated semaglutide 2.4 mg in the real-world: results from the SCORE—clinical ASCVD study
Nanna MG, Mena-Hurtado C, Divino V, et al.
Diabetes Obes Metab. Pub. online 26 Mar 2026.
Leggi
Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta‐analysis of randomised controlled trials
Eisa N, Barood O
Diabetes Obes Metab. Pub. online 24 Mar 2026.
Leggi
Waist-to-height ratio and the risk of cardiovascular outcomes and mortality in type 2 diabetes with and without abdominal obesity
Park KY, Han K, Park JH, et al.
Diabetes Obes Metab. Pub. online 24 Mar 2026.
Leggi